Aridis Pharmaceuticals is a biotechnology business based in the US. Aridis Pharmaceuticals shares (ARDS) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Aridis Pharmaceuticals employs 37 staff and has a trailing 12-month revenue of around $22.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.08 |
| 50-day moving average | $0.00 |
| 200-day moving average | $0.00 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.16 |
Historical closes compared with the close of $0.0001 from 2025-04-22
| 1 week (2025-04-16) | 0.0001 |
|---|---|
| 1 month (2025-03-25) | 0.0001 |
| 3 months (2025-01-24) | 0.0001 |
| 6 months (2024-10-25) | 0.0001 |
| 1 year (2024-04-23) | -99.84% |
|---|---|
| 2 years (2023-04-21) | -99.96% |
| 3 years (2022-04-22) | 1.32 |
| 5 years (2020-04-24) | 6.37 |
| Revenue TTM | $22.4 million |
|---|---|
| Gross profit TTM | $5.2 million |
| Return on assets TTM | -4.4% |
| Return on equity TTM | 0% |
| Profit margin | -5.11% |
| Book value | $-0.27 |
| Market Capitalization | $4,457 |
TTM: trailing 12 months
We're not expecting Aridis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aridis Pharmaceuticals's shares have ranged in value from as little as $0.0001 up to $0.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Aridis Pharmaceuticals's is -81.23. This would suggest that Aridis Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aridis Pharmaceuticals has bucked the trend.
Aridis Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.